Discovery Labs Prices $50 Million Public Offering of Common Stock

      Discovery Labs Prices $50 Million Public Offering of Common Stock

PR Newswire

WARRINGTON, Pa., Oct. 31, 2013

WARRINGTON, Pa., Oct. 31, 2013 /PRNewswire/ --Discovery Laboratories, Inc.
(NASDAQ: DSCO) today announced that it has priced an underwritten public
offering of 25 million shares of its common stock, at a price to the public of
$2.00 per share for gross proceeds of $50 million. Net proceeds, after
underwriting discount and other estimated fees and expenses payable by the
Company, are expected to be approximately $47 million. The offering is
expected to close on or about November 5, 2013, subject to satisfaction of
customary closing conditions. In addition, the underwriters have been granted
a 30-day option to purchase up to an additional 3.75 million shares of common
stock to cover over-allotments, if any. Stifel and Piper Jaffray & Co. are
acting as joint bookrunning managers for the offering, Lazard Capital Markets
LLC is acting as co-lead manager and Roth Capital Partners, LLC is acting as
co-manager.

The securities described above are being offered by Discovery Laboratories,
Inc. pursuant to a shelf registration statement on Form S-3, together with a
base prospectus, previously filed and declared effective by the Securities and
Exchange Commission (SEC). The securities may be offered only by means of a
prospectus, including a prospectus supplement, forming a part of the effective
registration statement. A preliminary prospectus supplement related to the
offering was filed with the SEC on October 30, 2013. When available, copies
of the final prospectus supplement and accompanying base prospectus relating
to this offering may be obtained at the Securities and Exchange Commission web
site at http://www.sec.gov, or from Stifel, Nicolaus & Company, Incorporated,
Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco,
California 94104 or via telephone at (415) 364-2500 or from Piper Jaffray &
Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,Minneapolis,
MN55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any securities of Discovery Laboratories, Inc. nor shall
there be any sale of the securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.

About Discovery Labs
Discovery Laboratories, Inc. is a specialty biotechnology company focused on
advancing a new standard in respiratory critical care. Discovery Labs' novel
proprietary KL4 surfactant technology produces a synthetic, peptide-containing
surfactant that is structurally similar to pulmonary surfactant. Discovery
Labs is also developing its proprietary drug delivery technologies to enable
efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.
Discovery Labs' strategy is initially focused on neonatology and improving the
management of respiratory distress syndrome (RDS) in premature infants.
Discovery Labs believes that its RDS product portfolio has the potential to
become the new standard of care for RDS and, over time, significantly expand
the current worldwide RDS market. For more information, please visit the
Company's website at www.Discoverylabs.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from the
statements made. Examples of such risks and uncertainties, including those
related to Discovery Labs' securities offering and its development programs,
are described in Discovery Labs' filings with the Securities and Exchange
Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and
any amendments thereto.

SOURCE Discovery Laboratories, Inc.

Website: http://www.discoverylabs.com
Contact: Company, John Tattory, Vice President of Finance, Discovery Labs -
215.488.9418; Investor Relations: Michael Rice, LifeSci Advisors -
646.597.6979
 
Press spacebar to pause and continue. Press esc to stop.